Manufacturer
Venus Remedies
Contents
Cisplatin
Indication
Metastatic non-seminomatous germ cell carcinoma. Advanced stage, refractory ovarian & bladder carcinoma. Refractory head & neck squamous cell carcinoma.
Instruction
Adult & childn Monotherapy 50-120 mg/m2 single dose every 3-4 wk or 15-20 mg/m2 daily for 5 days every 3-4 wk. Combination chemotherapy ≥20 mg/m2 once every 2-3 wk. Cervical cancer 40 mg/m2 wkly for 6 wk in combination w/ radiotherapy.
Drug interaction
Boosted myelosuppressive activity w/ myelosuppressives or radiation. Intensified nephrotoxicity occurrence w/ antihypertensives containing furosemide, hydralazine, diazoxide & propranolol. Potentiated renal toxic effects w/ cephalosporins, aminoglycosides, amphotericin B or contrast media. Potentially reduced renal elimination w/ cytostatic agents eg, bleomycin, methotrexate. Raynaud phenomenon w/ vinblastin. Renal toxicity & increased hearing loss w/ ifosfamide. Reduced lithium blood values w/ etoposide. Increased serum uric acid conc w/ allopurinol, colchicine, probenecid or sulfinpyrazone. Severe neurotoxic effects w/ docetaxel. Diminished effectiveness by chelating agents ie, penicillamine. Excessive immunosuppression w/ ciclosporin. Potentiated ototoxic effects w/ aminoglycosides, loop diuretics. Risk of fatal systemic vaccinal disease w/ yellow fever vaccine. Regularly check INR w/ oral anticoagulants. Masked ototoxicity symptoms w/ antihistamines, buclizine, cyclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides. Reduced absorption of phenytoin. Affected response time w/ pyroxidine + altretamine combination. Reduced clearance of paclitaxel.
Malaysia
